Avalo Therapeutics AVTX
NASDAQ AVTX
$15.58 +0.50 (+3.32%)
At close: Sep 29, 2026 · 4:00 PM EDT

Avalo Therapeutics (AVTX) Research & Development (2014 - 2026)

Updated

Avalo Therapeutics (AVTX) posted Research & Development of $23.42 million for Q2 2026, up 66.4% from $14.07 million a year earlier and up 66.7% from the prior quarter.

Analysis

Avalo Therapeutics (AVTX) Research & Development (2014 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Research & Development at Avalo Therapeutics was $64.35 million, up 57.3% year-over-year; for FY2025, it was $50.08 million, up 105.0% from FY2024.

  • Annual Research & Development shows a five-year compound annual growth rate of 9.2% (FY2020 to FY2025).
  • In prior years, Avalo Therapeutics' Research & Development was $24.44 million in FY2024 (+77.3%), $13.78 million in FY2023 (-56.0%), $31.31 million in FY2022 (-47.7%) and $59.84 million in FY2021 (+85.9%).
  • The Q2 2026 figure stands as the highest quarterly Research & Development since Q1 2021.
  • On a year-over-year basis, Research & Development has increased in each of the last eight quarters, with growth averaging 220.5% over the last eight quarters.
  • The strongest year-over-year quarter for Research & Development in the past five years was Q3 2024, with growth of 663.7%; the weakest was Q3 2023, with a decline of 82.3%.
  • According to Business Quant data, Research & Development for the three prior quarters was $14.05 million (Q1 2026), $13.27 million (Q4 2025) and $13.62 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 3.65 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.34 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 9.74 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -2.85 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -4.05 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn 1.87 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 1.76 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn 2.81 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn 993.80 Mn
10 Avalo Therapeutics 657.52 Mn 657.52 Mn - 23.42 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 23.42 Mn
Mar 31, 2026 14.05 Mn
Dec 31, 2025 13.27 Mn
Sep 30, 2025 13.62 Mn
Jun 30, 2025 14.07 Mn
Mar 31, 2025 9.12 Mn
Dec 31, 2024 8.18 Mn
Sep 30, 2024 9.54 Mn
Jun 30, 2024 4.60 Mn
Mar 31, 2024 2.12 Mn
Dec 31, 2023 1.87 Mn
Sep 30, 2023 1.25 Mn
Jun 30, 2023 4.66 Mn
Mar 31, 2023 6.01 Mn
Dec 31, 2022 6.17 Mn
Sep 30, 2022 7.04 Mn
Jun 30, 2022 8.51 Mn
Mar 31, 2022 9.58 Mn
Dec 31, 2021 11.51 Mn
Sep 30, 2021 10.55 Mn
API Access

Avalo Therapeutics Research & Development API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=research-and-development&ticker=AVTX&period=max&api_key=YOUR_API_KEY